Avance Biosciences expands cell, gene therapy research capabilities

By The Science Advisory Board staff writers

February 16, 2021 -- Contract research organization Avance Biosciences is expanding its Houston facility to meet growing demand for cell-based manufacturing.

The new facility is located adjacent to the company's existing facility and is expected to be completed in the third quarter of 2021. The additional 5,500 sq ft will be devoted to cell-based assay services and enable Avance to better address client needs related to good manufacturing practices.

Additionally, the company is expanding its mammalian cell culture-related assay capabilities, including mycoplasma testing, adventitious agents testing, sterility, and potency.

In 2020, Avance added 7,500 sq ft dedicated to next-generation sequencing and droplet digital polymerase chain reaction (PCR) capabilities to support edited gene testing, gene integration assays, and DNA/RNA biodistribution studies for gene therapy clients.

Science 37 launches CRO program for decentralized clinical trials
Science 37 has launched a partnership program called Science 37 Certified, which is designed to empower contract research organizations (CROs) with access,...
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.
Florida CRO expands drug screening and manufacturing
Florida-based contract research organization (CRO) Alchem Laboratories is constructing a new building to grow its screening and chemical trail manufacturing...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter